For F..s sake grow up the lot of you this is going nowhere. It is not being played by the MM s it is not being eyed up by big Phizas and it sure ain't going to get to 5 let alone 28 a share its boll..ckz and crap look at advinz
I don't think we have a floor until an institutional is on board. We do have an end date though so vc capital may have a look. I have discounted aurora. It's a bonus when if it happens. Chk1 will.pass p1 end 2017. 10m milestone guess. P2 end 2018 20m milestone when dnai will on licence it. And we will get a cut. Tyk2 is interesting. It's a variable thermostat. Cancer drugs it's maximum dose before side effects. Autoimmune it's getting the temperature just right. Just the right amount which depends on the disease and the patient. Which is going to take longer. More compounds. More preclinical. More trials. The good news is. Currently incurable diseases. As big as cancer market. Lifelong medicines. And despite the billions spent we appear to have the best in class molecules. So short term who knows. But 2 years I'm expecting full value and in the meantime a poacher may see the same. I personally think 2 big pharma are looking at tyk2 atm. But no hard facts just reading between the lines. Gla
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.